Next |
home / stock / celgz / celgz message board
Subject | By | Source | When |
---|---|---|---|
Will it bounce? | willlbone | investorshub | 09/26/2019 8:17:37 PM |
with 2.5% net sales cash payout in 2018 | celgz | investorshub | 02/01/2019 8:02:07 PM |
CELGZ buy 1.5266 | stocktrademan | investorshub | 08/24/2018 4:40:23 PM |
Eeek look like only 900 million this year. | 47cj2a | investorshub | 11/05/2015 11:23:46 PM |
Anyone still following this? Shouldn't Abraxane surpass | 47cj2a | investorshub | 09/28/2015 12:06:13 PM |
Chris DeMuth, Jr. Positions For 2015: Banking M&A, | Enterprising Investor | investorshub | 12/27/2014 3:38:52 AM |
so was milestone 1 not met as of | db7 | investorshub | 10/28/2014 1:29:33 PM |
Milestone Payment #2 was $6.9326 per CVR in 10/2013. | Enterprising Investor | investorshub | 08/24/2014 3:57:15 PM |
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement | Enterprising Investor | investorshub | 08/24/2014 3:51:26 PM |
CVR Terms: | Enterprising Investor | investorshub | 08/24/2014 3:39:03 PM |
Have an order in for $2.60. It | gotinearly | investorshub | 12/05/2013 4:55:02 PM |
$CELGZ is a contingent value right developed when | diamondsaagbf24k | investorshub | 10/10/2013 10:17:44 PM |
Why the cliff drop in PPS on the | RandolRocketman | investorshub | 10/10/2013 7:56:57 PM |
Nice bounce today | Edi13 | investorshub | 10/08/2013 7:17:06 PM |
I had it I think over a year. | Kinny | investorshub | 10/08/2013 6:04:35 PM |
Do you still watch this one? | UpTickMeA$AP | investorshub | 10/08/2013 3:34:08 PM |
What I like about the Celgene CVR is | Kinny | investorshub | 10/04/2012 12:57:16 PM |
NSCLC AND HEAD & NECK - found a | roadkilll | investorshub | 10/03/2012 2:49:07 PM |
Why is this CVR so cheap? | roadkilll | investorshub | 10/03/2012 2:29:35 PM |
When CVR was created | roadkilll | investorshub | 10/01/2012 11:08:57 PM |
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Contingent Value Right Company Name:
CELGZ Stock Symbol:
NASDAQ Market:
Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights (NASDAQ: CELGZ) (“Celg...